The influence of inhibiting Notch signal on pulmonary vascular remodeling induced by PDGF

Journal of Sichuan University (Medical Science)

Volumn 42, Issue 6, 2011, Pages 766-770

  Qiao, Li Na ^a   Wang, Xian Min ^b   Liu, Zhong Qiang ^a   Wang, Xiao Qin ^a   Zhou, Tong Fu ^a   Hua, Yi Min ^a   Liu, Han Min ^a  

^a SICHUAN UNIVERSITY   (China)

^b CHENGDU WOMEN S AND CHILDREN S CENTRAL HOSPITAL   (China)

Author keywords

Notch signal; Platelet derived growth factor; Pulmonary; Vascular remodeling

Indexed keywords

EID: 82655181543     PISSN: 1672173X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Stenmark KR, Fagan KA, Frid MG. Hypoxia-induced pulmonary vascular remodeling cellular and molecular mechanisms. Circ Res, 2006;99(7):675-691. (Pubitemid 44498302)
2. Chan SY, Loscalzo J. Pathogenic mechanisms of pulmonary arterial hypertension. J Mol Cell Cardiol, 2008;44(1):14-30.
3. Hofmann JJ, Iruela-Arispe ML. Notch signaling in blood vessels: who is talking to whom about what? Circ Res. 2007;100(11):1556-1568. (Pubitemid 46897259)
4. Ehebauer M, Hayward P, Arias AM. Notch, a universal arbiter of cell fate decision. Science, 2006;314(5804):1414-1415. (Pubitemid 44871939)
5. Morrow D, Guha S, Sweeney C, et al. Notch and vascular smooth muscle cell phenotype. Cir Res, 2008;103(12):1370-1382.
6. Kurpinski K, Lam H, Chu J, et al. Transforming growth factor-beta and notch signaling mediate stem cell differentiation into smooth muscle cells. Stem Cell, 2010;28(4):734-742.
7. Kennard S, Liu H, Lilly B. Transforming growth factor-beta (TGF-1) down-regulates Notch3 in fibroblasts to promote smooth muscle gene expression. J Biol Chem, 2008;283(3):1324-1333.
8. Hellstrom M, Phng LK, Hofmann JJ, et al. D114 signalling through Notchl regulates formation of tip cells during angiogenesis. Nature, 2007;445(15):776-780. (Pubitemid 46279716)
9. Schermuly RT, Dony E, Ghofrani HA, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest, 2005;115(10):2811- 2821. (Pubitemid 41434408)
10. Hatano M, Yao A, Shiga T, et al. Imatmib mesylate has the potential to exert its efficacy by down-regulating the plasma concentration of platelet-derived growth factor in patients with pulmonary arterial hypertension. Int Heart J, 2010;51(4):572-576.
11. Grimminger F, Schermuly RT. PDGF receptor and its antagonists: role in treatment of PAH. Adv Exp Med Biol, 2010;661:435-446.
12. Chhina MK, Nargues W, Grant GM, et al. Evaluation of imatinib mesylate in the treatment of pulmonary arterial hypertension. Future Cardiol, 2010;6(1):19-35.
13. Selimovic N, Bergh CH, Andersson B, et al. Growth factors and interleukin-6 across the lung circulation in pulmonary hypertension. Eur Respir J, 2009:34(3):662-668.
14. Perros F, Montani D, Dorfmuller P, et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med, 2008;178(1):81-88. (Pubitemid 351919196)
15. Morohashi Y, Kan T, Tominari Y, et al. C-terminal fragment of presenilin is the molecular target of a dipeptidic γ-secretasespecific inhibition DAPT (N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-Butyl Ester). J Biol Chem, 2006;281(21):14670-14676. (Pubitemid 43855171)